Altered serum levels of type I collagen turnover indicators accompanied by IL-6 and IL-8 release in stable COPD

Ying-Ying Zeng¹
Wei-Ping Hu¹
Yi-Hui Zuo¹
Xiao-Ru Wang²
Jing Zhang¹

¹Department of Pulmonary Medicine, Zhongshan Hospital, Fudan University, Shanghai, China; ²Department of Pulmonary Medicine, Dahua Hospital, Shanghai, China

Background: COPD, characterized by chronic inflammation and airway remodeling, has significant pathological alterations in composition and deposition of the extracellular matrix. The expression of procollagen 1 C-terminal peptide (PICP) and collagen type 1 C-terminal telopeptide (ICTP), two major by-products in the synthesis and degradation of collagen, was shown to be positively correlated with inflammatory mediator levels in previous studies.

Purpose: In this study, we investigated whether the serum concentrations of PICP and ICTP were associated with the inflammation level for patients with stable COPD.

Patients and methods: We collected serum samples from 25 control subjects and 20 patients with stable COPD from December 2011 to October 2012 in Shanghai Zhongshan Hospital and Shanghai Dahua Hospital. We determined concentrations of PICP, ICTP, C-reactive protein (CRP), IL-6, IL-8, and tumor necrosis factor (TNF)-α by using enzyme-linked immunosorbent assay methods.

Results: Demographic characteristics were comparable between the two groups. In patients with stable COPD, serum levels of CRP, IL-6, IL-8, and TNF-α were all elevated compared to control subjects, but only changes of IL-6 achieved statistical significance. Serum concentration of PICP was significantly elevated in patients with COPD, and level of ICTP was slightly decreased. Moreover, serum concentrations of PICP were positively correlated with the levels of both IL-6 and IL-8.

Conclusion: The increased levels of serum PICP in COPD might indicate the condition of airway remodeling, and IL-6 and/or IL-8 might play an important role in stimulating collagen synthesis.

Keywords: chronic obstructive pulmonary disease, COPD, procollagen type I C-terminal peptide, PICP, C-terminal telopeptide of type I collagen, ICTP, interleukin-6, IL-6, interleukin-8, IL-8

Introduction
COPD is one of the leading causes of mortality and morbidity around the world, causing a huge and growing economic and social burden.¹⁰⁴ Chronic inflammation and irreversible airflow obstruction are the main characteristics of COPD, often accompanied by structural changes of the lung.¹³ This chronic inflammation response may induce parenchymal tissue destruction and recomposition of extracellular matrix (ECM). In the lung, type I collagen could form a tight fibrillar network throughout the large conducting airways, bronchi, and bronchioles, providing the mechanical strength and stability required for their proper functions.⁶⁷ Furthermore, among a variety of proteins participating in the progression of small airway remodeling in COPD,
type I collagen was the predominant constituent of the altered ECM composition.5

In the process of type I collagen synthesis, type I procollagen chains are firstly polymerized to form procollagen trimer from the C-terminus nucleation. Then, after shedding the C-terminus trimeric nucleus which is known as procollagen type I C-terminal peptide (PICP), the trimer is deposited in tissues as the insoluble fibrillary collagen. Additionally, mature type I collagen with type-specific collagen cross-links can liberate from tissues and regain solubility via enzymatic degradation into small fragments, and the C-terminal telopeptide is known as C-terminal telopeptide of type I collagen (ICTP).6,9 Therefore, the expression and release of PICP and ICTP could reflect the ongoing turnover of deposition and degradation of type I collagen in tissues.

In a previous study of asthma, airway inflammatory factors could affect the levels of ICTP and PICP in sputum.10 Moreover, PICP and ICTP, were involved in the airway remodelling caused by the disorder of ECM deposition. Similar to asthma, small airway remodelling is one of the pathological mechanisms of COPD.11 Taking these facts together, we hypothesized that the imbalanced collagen turnover in COPD lung might be reflected by circulating levels of PICP and ICTP, which could be accompanied by the release of inflammatory factors.

To validate this hypothesis, we performed a multicenter cohort study to investigate whether serum levels of PICP and ICTP were different between patients with stable COPD and healthy subjects and further analyzed the association between these markers and some clinical variables, such as smoke exposure, lung function, and inflammatory markers.

Patients and methods
Study population
Subjects in this study were recruited from Zhongshan Hospital of Fudan University (a tertiary teaching hospital) and Shanghai Dahua Hospital (a secondary district hospital) from December 2011 to October 2012. Participants without COPD from a general population were recruited into the control group, and stable COPD patients aged 45 years and older were enrolled into the COPD group. Subjects with stable COPD were mainly recruited from respiratory outpatient departments and respiratory wards. The diagnosis of COPD was made according to the GOLD criteria. Briefly, COPD was diagnosed when post-bronchodilator FEV1/FVC ratio was <0.70.4

Participants who met any of the following criteria were excluded: 1) patients with congestive heart failure, pneumoconiosis, asthma, bronchiectasis, active pulmonary tuberculosis, interstitial lung disease, obstructive bronchiolitis, pleural effusion, diffuse panbronchiolitis, lung cancer, or a history of pneumonectomy; 2) those having large airway abnormality that caused respiratory symptoms similar to COPD and/or airflow limitation; 3) exacerbation of COPD within 4 weeks; 4) patients with medical records of osteoporosis or bone metastasis of malignant tumors; and 5) those who had been taking oral or intravenous corticosteroid for treating other diseases.

Study procedure and data collection
For all participants, baseline characteristics and lung function were recorded. Baseline characteristics included age, gender, weight, height, smoking status (never smoker, ever smoker, or current smoker), pack-years of smoking, and number of acute exacerbations in the previous year. Non-smokers were defined as having <5 pack-years of cigarettes; otherwise, the subjects were classified as smokers. Spirometric measurements were performed according to international guidelines using a calibrated MS-PFT spirometer (Jaeger Co, Hoechberg, Germany) before and after inhalation of 400 µg salbutamol.12 Serum samples were collected for subsequent measurement of C-reactive protein (CRP), IL-6, IL-8, tumor necrosis factor-α (TNF-α), PICP, and ICTP.

For patients with COPD, results of extra two questionnaires – COPD assessment test and modified Medical Research Council scale – were collected for evaluating health status impairment and dyspnea.13,14 The COPD grade based on FEV1 % was calculated as shown in Table 1. COPD severity group was also assessed according to A, B, C, D classification proposed by GOLD reports.4

Quantification of biomarkers in serum samples
Commercial ELISA kits used for measuring serum levels of IL-6 (cat no SEA079Hu), IL-8 (cat no SEA080Hu), TNF-α (cat no SEA133Hu), and PICP (cat no SEA570Hu) were

<table>
<thead>
<tr>
<th>Table 1</th>
<th>Definition and severity grading of COPD according to degree of airflow obstruction</th>
</tr>
</thead>
<tbody>
<tr>
<td>Grade</td>
<td>Post-bronchodilator spirometry test</td>
</tr>
<tr>
<td>Grade 1 (mild COPD)</td>
<td>FEV1/FVC &lt;70%; FEV1%pred ≥80%</td>
</tr>
<tr>
<td>Grade 2 (moderate COPD)</td>
<td>FEV1/FVC &lt;70%; 50% ≤ FEV1%pred &lt;80%</td>
</tr>
<tr>
<td>Grade 3 (severe COPD)</td>
<td>FEV1/FVC &lt;70%; 30% ≤ FEV1%pred &lt;50%</td>
</tr>
<tr>
<td>Grade 4 (very severe COPD)</td>
<td>FEV1/FVC &lt;70%; FEV1%pred &lt;30% or FEV1%pred &lt;50% plus chronic respiratory failure</td>
</tr>
</tbody>
</table>

Abbreviation: %pred, percentage of predicted.
purchased from Uscn Life Science Inc (Wuhan, China). The commercial competitive radioimmunoassay kits were used to measure serum levels of ICTP (cat no 06099; UniQ, Orion Diagnostica, Espoo, Finland). These procedures were performed according to the manufacturer’s instructions.

Ethics statement
This study was approved by the Ethics Committee of Zhongshan Hospital of Fudan University and registered in the Chinese Clinical Trials Registry (ChiCTR-OCC-11001621). This study was conducted in accordance with the Declaration of Helsinki and written informed consent was received from all participants.

Statistical analysis
Statistical analyses were performed using SPSS version 19.0 (SPSS Inc, Chicago, IL, USA). All continuous variables were expressed as mean ± SEM. D’Agostino and Pearson omnibus normality test was performed for continuous variables. For normally distributed data, unpaired t-tests or one-way ANOVA followed by Bonferroni post-test was performed to determine whether the differences between the groups were statistically significant. Otherwise, comparisons were made using Mann–Whitney test or Kruskal–Wallis analysis followed by Dunn’s multiple comparison test. Correlation analyses were carried out using Pearson or Spearman methods depending on the normality of data distribution. For categorical variables, a chi-squared (χ²) test and Spearman rank correlation analysis were used to make comparisons between groups. Differences were considered significant at the level of P<0.05.

Results
Baseline characteristics
In our study, a total of 20 patients with stable COPD and 25 controls without COPD were recruited, including 13 male, 7 female in the COPD group and 16 male, 9 female in the control group. Demographic data, smoking habit, COPD grade based on post-bronchodilator FEV₁/ème, and COPD severity group are described in Tables 2 and 3. Age and gender had no significant difference between the COPD group and the control group. Subjects with COPD smoked more heavily than controls, but the differences were not statistically significant.

Inflammatory biomarkers
As shown in Table 4, serum levels of CRP, IL-6, IL-8, and TNF-α were all increased in patients with stable COPD compared to control subjects without COPD, but only changes of IL-6 had a statistically significant difference.

Table 2 Baseline characteristics between control and COPD groups

<table>
<thead>
<tr>
<th>Characteristics</th>
<th>Control</th>
<th>COPD</th>
<th>P-value</th>
</tr>
</thead>
<tbody>
<tr>
<td>N</td>
<td>25</td>
<td>20</td>
<td>0.956</td>
</tr>
<tr>
<td>Male/female, n</td>
<td>16/9</td>
<td>13/7</td>
<td>0.258</td>
</tr>
<tr>
<td>Age (years)</td>
<td>73.1±2.6</td>
<td>78.3±1.7</td>
<td>0.098</td>
</tr>
<tr>
<td>Smoker/non-smoker, n</td>
<td>10/15</td>
<td>12/8</td>
<td>0.192</td>
</tr>
<tr>
<td>Pack-years</td>
<td>10.8±3.2</td>
<td>22.4±5.2</td>
<td>0.098</td>
</tr>
<tr>
<td>FEV₁, post-bronchodilator, L</td>
<td>1.628±0.123</td>
<td>0.878±0.051</td>
<td>&lt;0.001</td>
</tr>
<tr>
<td>FEV₁/FEVC, %</td>
<td>74.6±5.0</td>
<td>45.2±2.2</td>
<td>&lt;0.001</td>
</tr>
<tr>
<td>ICTP, %pred, post-bronchodilator, %</td>
<td>78.5±1.9</td>
<td>57.1±2.3</td>
<td>&lt;0.001</td>
</tr>
</tbody>
</table>

Table 3 Combined assessment of severity conditions for patients with COPD

<table>
<thead>
<tr>
<th>Combined COPD assessment</th>
<th>GOLD grade</th>
<th>GOLD group</th>
</tr>
</thead>
<tbody>
<tr>
<td>Grade 1/group A, n (%)</td>
<td>0 (0)</td>
<td>0 (0)</td>
</tr>
<tr>
<td>Grade 2/group B, n (%)</td>
<td>9 (45)</td>
<td>3 (15)</td>
</tr>
<tr>
<td>Grade 3/group C, n (%)</td>
<td>11 (55)</td>
<td>1 (5)</td>
</tr>
<tr>
<td>Grade 4/group D, n (%)</td>
<td>0 (0)</td>
<td>16 (80)</td>
</tr>
</tbody>
</table>
significance in patients with COPD. Moreover, the expression of PICP was positively correlated with serum IL-6 and IL-8 concentration. However, no correlation was found between the serum levels of ICTP and IL-6 or IL-8 in COPD patients.

Abnormal and excessive deposition of the ECM in small airway walls is a major pathological processes in COPD,7,15 in which type I collagen is an important molecule. The amount of insoluble collagen in tissues is mainly regulated by the process of synthesis and degradation,7 and PICP is a reliable biomarker of synthesis of type I collagen.16 Thus, the increased concentration of PICP in the serum of COPD patients indicates that PICP might be associated with the occurrence and progression of airway remodeling. Furthermore, we speculate that the serum concentration of PICP may be correlated with the severity of COPD, but further research is needed to confirm this hypothesis. Significant differences between PICP and FEV1% were not observed, probably due to the small sample size.

Some previous studies demonstrate that IL-6 is released from fibroblasts, endothelial cells, and epithelial cells in COPD, and could induce collagen synthesis.17–19 Consistent with these studies, we also observed the increased concentration of IL-6 in the COPD group.

In our study, the concentration of PICP in serum was positively correlated with the concentration of IL-6 and IL-8 in the serum. Some studies showed that rhIL-6 could infiltrate in the peritendinous tissue, resulting in a remarkable increase of the peritendinous concentration of PICP.20 Moreover, animal studies proved that IL-6-knockdown mice had declined concentrations of PICP compared with normal mice.20 Therefore, the correlation of IL-6 and PICP in COPD patients indicated that IL-6 could promote the deposition of ECM in airways and the development of airway remodeling by cooperating with PICP. IL-8, a chemotactic factor for neutrophils, has been confirmed to be responsible for acute exacerbation and disease progression of COPD.21 Our previous study demonstrated that IL-6 and IL-8 were mainly produced by pulmonary fibroblasts and could participate in the maintenance of the persistent inflammation in COPD lungs.22 Taking these findings into account, we postulated that both IL-6 and IL-8 could promote collagen synthesis and ECM deposition in COPD. However, the mechanism of IL-6 and/or IL-8 in stimulating the production of PICP in COPD has not yet been elucidated. The association between ICTP and IL-6 or IL-8 was not found in our study (data not shown). A large sample may be needed to testify our results.

Our study has limitations. Firstly, since the sample size was small, the results may be biased and could not represent the overall COPD populations. Secondly, diseases other than COPD could affect the levels of PICP and ICTP in COPD patients, including osteoporosis, glucocorticoids, and metastatic bone cancer.10,23,24 As the critical factors in bone synthesis and resorption, PICP and ICTP are closely associated with the development of osteoporosis.25 At the same time, osteoporosis is one of the common comorbidities in COPD patients, with a prevalence rate of 22%–44%. In addition,
Table 5 Correlation analysis between serum levels of PICP, clinical variables, and inflammatory biomarkers

<table>
<thead>
<tr>
<th>Variables</th>
<th>Serum levels of PICP</th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td>Smoking (pack-year)</td>
<td>0.134</td>
<td>0.411</td>
</tr>
<tr>
<td>FEV₁ %pred (%)</td>
<td>−0.250</td>
<td>0.119</td>
</tr>
<tr>
<td>FEV₁/FVC% (%)</td>
<td>−0.251</td>
<td>0.118</td>
</tr>
<tr>
<td>CRP (mg/L)</td>
<td>0.077</td>
<td>0.646</td>
</tr>
<tr>
<td>IL-6 (pg/mL)</td>
<td>0.483</td>
<td>&lt;0.001</td>
</tr>
<tr>
<td>IL-8 (pg/mL)</td>
<td>0.472</td>
<td>0.001</td>
</tr>
<tr>
<td>TNF-α (pg/mL)</td>
<td>0.220</td>
<td>0.147</td>
</tr>
</tbody>
</table>

Abbreviations: PICP, procollagen type I C-terminal peptide; %pred, percentage of predicted; CRP, C-reactive protein; TNF, tumor necrosis factor.

Discourse

The association between PICP and IL-6, IL-8 in COPD

References

The authors report no conflicts of interest in this work.

References


